Questions for ASCO – on Tamoxifen, ATLAS and aTTom

The problem with Tamoxifen is that it has anti-estrogen effects that many young (and older) women consider undesirable. Already our breasts have been cut. Feeling “feminine” is not trivial.

Posted in Breast Cancer, cancer treatment, clinical trials, Medical News, Oncology (cancer), Women's HealthTagged , , , , , , , , 3 Comments on Questions for ASCO – on Tamoxifen, ATLAS and aTTom

When Less Chemo is Just As Good, In Treatment for Acute Myeloid Leukemia (AML)

Today’s issue of the New England Journal of Medicine includes an article with the bland title Cytarabine Dose for Acute Myeloid Leukemia. AML is an often-curable form of leukemia characterized by rapidly-growing myeloid white blood cells. Cytarabine – what we’d call “Ara-C” on rounds¬† – has been a mainstay of AML treatment for decades. The […]

Posted in cancer treatment, clinical trials, Oncology (cancer), Under the RadarTagged , , , , , , Leave a Comment on When Less Chemo is Just As Good, In Treatment for Acute Myeloid Leukemia (AML)
newsletter software